CCSD Code K2310: Excision of Cardiac Tumour

Key Takeaways

K2310 covers excision of benign and malignant cardiac tumours via open-heart surgery

Pre-authorisation required by major UK insurers before procedure scheduling

Documentation must include cardiopulmonary bypass records and tumour histology

Fee schedules vary by insurer: Bupa £8,500-£12,000, AXA PPP £9,000-£13,500

Code excludes pericardial tumours and thoracoscopic approaches (separate codes apply)

CCSD Code K2310: Excision of cardiac tumour is the UK private healthcare billing code for open surgical removal of tumours located within the heart muscle or cardiac chambers. Maintained by Clinical Coding and Schedule Development (CCSD), this code applies to both benign lesions like myxomas and malignant tumours requiring cardiopulmonary bypass. Private cardiac surgery centres use K2310 to invoice insurers for complex procedures performed by cardiothoracic surgeons, typically in tertiary cardiac units equipped for open-heart operations.

UK insurers including Bupa, AXA PPP Healthcare, Vitality Health, Aviva, and WPA recognise K2310 for cardiac tumour excision claims. Fee schedules reflect the procedure’s technical complexity, anaesthetic requirements, and intensive care unit (ICU) aftercare. Documentation standards require operative notes detailing tumour location, bypass time, and histopathological confirmation. Coding accuracy directly affects claim approval rates, with undercoding leading to revenue loss and overcoding triggering audit flags from insurers and the Private Healthcare Information Network (PHIN).

What Is CCSD Code K2310: Excision of Cardiac Tumour?

CCSD Code K2310: Excision of cardiac tumour covers open surgical procedures to remove benign or malignant tumours from the heart. Primary cardiac tumours are rare, with an incidence of 0.001-0.03% in autopsy series, but require prompt surgical intervention when detected. Benign lesions account for 75% of primary cardiac tumours, with myxomas representing 50% of these cases. Malignant tumours, predominantly sarcomas, comprise the remaining 25%.

The code applies when the surgeon performs median sternotomy, establishes cardiopulmonary bypass, and excises the tumour under direct vision with cardioplegic arrest. Tumour location determines surgical approach: atrial tumours often allow resection through an atriotomy, while ventricular tumours may require ventriculotomy with reconstruction. According to Bupa’s code search system, K2310 includes excision with primary closure or patch repair of the cardiac chamber.

CCSD Code K2310: Excision of cardiac tumour excludes pericardial tumours (coded separately under K2500 series) and minimally invasive approaches via thoracoscopy (coded under K2340 series). The code also excludes biopsy-only procedures without excision, coded under K2701 for cardiac biopsy. Surgeons must document the complete removal of the tumour mass to justify K2310 billing rather than biopsy codes.

Typical patient pathways involve initial diagnosis via echocardiography or cardiac MRI, followed by multidisciplinary team (MDT) discussion including cardiothoracic surgeons, cardiologists, and oncologists. Surgical timing depends on tumour size, growth rate, and symptoms. Embolic complications from atrial myxomas or haemodynamic obstruction from large ventricular tumours necessitate urgent intervention. Malignant tumours require coordination with oncology for neoadjuvant or adjuvant therapy planning.

Clinical Indications for K2310 Cardiac Tumour Excision

Cardiac tumour excision under K2310 proceeds when imaging confirms a mass amenable to surgical resection and the patient’s cardiac function tolerates cardiopulmonary bypass. Atrial myxomas present with embolic phenomena in 30-40% of cases, including stroke, limb ischaemia, or splenic infarction. Ventricular tumours cause outflow tract obstruction, arrhythmias, or heart failure symptoms. Malignant tumours demonstrate rapid growth on serial imaging, with infiltration into adjacent structures indicating aggressive histology.

Pre-operative workup includes transthoracic and transoesophageal echocardiography to map tumour attachment, mobility, and chamber involvement. Cardiac MRI with gadolinium contrast differentiates thrombus from tumour and assesses myocardial infiltration. Coronary angiography rules out coronary artery disease before bypass, particularly in patients over 40 years or with cardiac risk factors. Chest CT excludes pulmonary metastases when malignancy is suspected.

Surgical decision-making weighs operative risk against natural history. Benign tumours like myxomas warrant excision due to embolic risk and potential for sudden death from valve obstruction. Malignant tumours present complex decisions: localised sarcomas may benefit from complete resection followed by chemotherapy, while metastatic disease shifts management toward palliative care. The cardiothoracic MDT documents these deliberations in pre-operative notes, which insurers review when assessing K2310 claims for medical necessity.

Contraindications to K2310 surgery include severe left ventricular dysfunction (ejection fraction below 25%), active infection, and widespread metastatic disease. Relative contraindications involve advanced age, significant comorbidities, or patient refusal of blood transfusion. In such cases, alternative management including watchful waiting for small asymptomatic myxomas or palliative care for malignant tumours replaces surgical excision. Documentation of shared decision-making and contraindication rationale supports coding integrity when K2310 is not pursued despite tumour presence.

K2310 Surgical Procedure and Technical Requirements

CCSD Code K2310: Excision of cardiac tumour procedures follow a standardised operative sequence. The cardiothoracic surgeon performs median sternotomy to access the heart, establishes cardiopulmonary bypass via aortic and bicaval cannulation, and cools the patient to 28-32°C. Once bypass is stable, aortic cross-clamping and cardioplegic arrest allow safe opening of the cardiac chamber containing the tumour.

Atrial tumours typically attach to the interatrial septum near the fossa ovalis. The surgeon performs a right or left atriotomy, identifies the tumour stalk, and excises the mass with a margin of normal atrial tissue. Reconstruction involves primary suture closure or patch repair using autologous pericardium or synthetic material. Ventricular tumours require ventriculotomy, with excision guided by frozen section to ensure clear margins. Large defects necessitate patch reconstruction to maintain ventricular geometry.

Cardiopulmonary bypass time for K2310 procedures ranges from 90 to 180 minutes depending on tumour size, location, and reconstruction complexity. Cross-clamp time averages 60-120 minutes. Prolonged bypass increases postoperative complications including bleeding, renal dysfunction, and neurological events. Surgeons document bypass parameters in operative notes, which insurers cross-reference against K2310 fee schedules when processing claims.

Specimen handling follows oncological principles for malignant tumours and histopathological confirmation for benign lesions. The excised tumour undergoes immediate frozen section to guide margin adequacy, followed by permanent section with immunohistochemistry. Myxomas show characteristic stellate cells in a myxoid matrix. Sarcomas require subtype classification (angiosarcoma, rhabdomyosarcoma, leiomyosarcoma) to guide adjuvant therapy. Pathology reports form part of the K2310 documentation bundle submitted to insurers.

Documentation Requirements for K2310 Claims

Complete K2310 documentation begins with pre-operative imaging reports demonstrating the cardiac tumour. Echocardiography reports must describe tumour size (measured in centimetres), location (atrial or ventricular, chamber-specific), attachment point, and mobility. Cardiac MRI reports add tissue characterisation, perfusion patterns, and myocardial infiltration assessment. These imaging reports establish medical necessity for surgical intervention under CCSD Code K2310: Excision of cardiac tumour.

The operative note forms the core K2310 documentation. Required elements include incision type (median sternotomy), bypass cannulation sites (aortic and bicaval), cardioplegia delivery method (antegrade or retrograde), chamber access approach (atriotomy or ventriculotomy), tumour description (size, attachment, appearance), excision technique (complete or debulking), and reconstruction method (primary closure or patch). Aviva’s fee schedule guidelines specify that incomplete operative notes delay claim processing by 30-60 days pending clarification.

Cardiopulmonary bypass records document total bypass time, cross-clamp time, cooling and rewarming temperatures, and cardioplegia volumes. These parameters directly correlate with procedural complexity and reimbursement levels. Bypass times under 120 minutes may trigger queries when paired with K2310 codes for large tumours, suggesting inadequate excision or incomplete documentation. Accurate time recording prevents disputes during insurer audits.

Histopathology reports close the documentation loop. The pathology service provides frozen section findings (intra-operative), permanent section diagnosis (within 5-7 days), and immunohistochemistry results (within 10-14 days). Benign diagnoses like myxoma support single-stage K2310 coding. Malignant diagnoses trigger additional coding for lymph node sampling (if performed) and coordination with oncology for adjuvant therapy. Insurers cross-check pathology against operative findings to detect coding discrepancies.

K2310 Fee Schedules Across UK Private Insurers

CCSD Code K2310: Excision of cardiac tumour reimbursement varies by insurer, hospital location, and consultant experience. Bupa’s recognised fee schedule lists K2310 between £8,500 and £12,000, with teaching hospitals in London commanding higher rates than regional centres. AXA PPP Healthcare’s procedure code system brackets K2310 fees at £9,000 to £13,500, reflecting the need for 24-hour ICU care and extended hospital stays averaging 7-10 days.

Vitality Health applies a tiered fee structure: consultant cardiothoracic surgeons on their recognised provider list receive £10,500 for straightforward atrial myxoma excision under K2310, rising to £14,000 for complex ventricular tumours requiring extensive reconstruction. Vitality’s fee finder tool shows regional variation, with South East England procedures priced 15-20% above Midlands equivalents.

WPA and Aviva use reference pricing models linking K2310 fees to NHS National Tariff equivalents plus a private care premium. WPA’s medical fees schedule sets K2310 at 175% of the NHS reference cost, currently £11,200 for uncomplicated cases. Aviva adds facility fees covering operating theatre time, perfusion services, and cardiac ICU bed-days, pushing total claim values to £18,000-£25,000 when anaesthesia and hospital charges are included.

Fee negotiations between consultants and insurers occur annually, with K2310 rates subject to revision based on claims frequency, complication rates, and market benchmarking. Surgeons performing fewer than 10 K2310 procedures annually may face fee reductions or removal from preferred provider panels. High-volume centres with outcomes data demonstrating below-average complication rates negotiate premium fees, leveraging their track record during contract renewals.

Unbundling remains contentious for K2310 claims. Insurers expect the code to include all intra-operative components: cardiopulmonary bypass, cardioplegia, tumour excision, and chamber reconstruction. Separate billing for bypass (K3001) or cardioplegia administration (K3002) alongside K2310 triggers audits. However, additional procedures performed during the same operation-such as coronary artery bypass grafting (K4501) or valve replacement (K2501)-warrant separate coding when clinically indicated and documented as distinct interventions beyond tumour excision.

Streamline your cardiac surgery billing with Pabau

Track K2310 pre-authorisations, document bypass times automatically, and submit compliant claims to UK insurers-all from one platform designed for private healthcare providers.

Book a demo

Pre-Authorisation Requirements for K2310

UK private insurers mandate pre-authorisation for CCSD Code K2310: Excision of cardiac tumour before scheduling surgery. The pre-authorisation process involves submitting clinical documentation to the insurer’s medical management team, who assess medical necessity, verify policy coverage, and approve estimated costs. Failure to obtain pre-authorisation results in claim denial regardless of clinical appropriateness, shifting the financial burden to the patient or hospital.

Bupa requires a pre-authorisation form completed by the operating surgeon, accompanied by echocardiography or MRI reports, ECG tracings, and a proposed date of surgery. Submissions through Bupa’s online portal receive responses within 5-7 working days for elective cases. Emergency K2310 procedures for embolic complications or haemodynamic instability allow retrospective authorisation within 24 hours of surgery, provided the clinical team documents the urgency rationale.

AXA PPP Healthcare pre-authorisation distinguishes between benign and malignant tumours. Benign myxoma excision under K2310 receives streamlined approval based on imaging confirmation and consultant recommendation. Malignant tumours trigger enhanced review involving insurer-appointed cardiac surgeons who assess resectability, metastatic disease burden, and expected survival benefit. This extended review adds 10-14 days to the authorisation timeline, requiring surgery scheduling to account for potential delays.

Vitality Health and Aviva implement clinical criteria checklists for K2310 pre-authorisation. Criteria include tumour size exceeding 3cm, symptoms attributable to the tumour (dyspnoea, arrhythmia, embolic events), and absence of contraindications to cardiopulmonary bypass. Imaging reports must quantify these parameters; generic statements like “large cardiac mass” without measurements result in requests for additional information, delaying authorisation. Digital form capture systems help surgical teams standardise documentation to meet insurer-specific criteria.

WPA’s pre-authorisation process for K2310 includes cost estimation transparency. The insurer provides patients with a breakdown showing surgeon fees, anaesthetist fees, hospital facility charges, and estimated ICU costs. Patients with limited cardiac surgery coverage under their policy receive notification of any out-of-pocket expenses before proceeding. This financial counselling reduces post-operative payment disputes when final claims exceed initial estimates due to complications requiring extended ICU stays or reoperation.

Common K2310 Claim Denials and Appeals

K2310 claim denials fall into three categories: documentation deficiencies, medical necessity disputes, and procedural bundling disagreements. Documentation denials account for 40% of rejected K2310 claims, with incomplete operative notes or missing pathology reports as primary causes. Insurers issue requests for additional information (RAIs), suspending payment until providers submit missing documents. A 30-day response window applies; claims remaining incomplete after this period move to denial status, requiring formal appeals.

Medical necessity denials challenge whether cardiac tumour excision was clinically appropriate. Insurers question K2310 procedures for asymptomatic small myxomas under 2cm, arguing for watchful waiting over immediate surgery. Successful appeals require evidence supporting intervention: rapid growth on serial imaging, proximity to valves risking obstruction, or patient-specific factors like young age favouring definitive treatment. Expert opinion letters from independent cardiac surgeons strengthen appeals when insurer medical reviewers maintain their initial denial stance.

Bundling disputes arise when surgeons separately code procedures the insurer considers inclusive to K2310. For example, coding K2310 for tumour excision plus K3001 for cardiopulmonary bypass triggers automatic denial of the bypass code, with the insurer arguing bypass is inherent to K2310. The CCSD technical guide clarifies bundling rules: procedures essential to performing the primary intervention bundle into that code, while distinct procedures addressing separate pathology warrant independent coding.

Timing denials occur when insurers identify K2310 claims for recurrent tumours within 90 days of initial excision. Insurers interpret early recurrence as incomplete initial excision or inadequate operative technique, denying the second claim as correction of the first surgery. Successful appeals demonstrate recurrent tumour on pathology as distinct tissue growth rather than residual disease, supported by imaging showing tumour-free intervals between procedures. This distinction determines whether the second K2310 codes as a new procedure or no-cost revision.

Appeal success rates for K2310 denials reach 60-70% when providers address the specific denial reason with targeted documentation. Generic appeal letters restating clinical facts fail; effective appeals map new evidence directly to the insurer’s stated objection. For documentation denials, submitting the missing operative note resolves the issue. For medical necessity denials, providing published guidelines supporting intervention for the specific tumour characteristics converts denials to approvals. Persistent denials after exhausting internal appeals escalate to independent review organisations, extending resolution timelines to 120-180 days.

K2310 Coding Accuracy and Compliance

Accurate K2310 coding requires distinguishing cardiac tumour excision from related cardiothoracic procedures sharing similar surgical approaches but different code assignments. Pericardial tumours, for instance, fall under K2500 series codes despite requiring sternotomy and potential cardiopulmonary bypass. The anatomical distinction-cardiac chamber involvement versus pericardial sac-determines code selection. Surgeons must specify in operative notes whether the tumour arises from myocardium or pericardium to support correct coding.

Thoracoscopic approaches to small atrial tumours use K2340 series codes rather than K2310, even when the tumour type is identical. The surgical approach (minimally invasive versus open) dictates code assignment. Mixing open and thoracoscopic codes on the same claim triggers audits, with insurers requesting video recordings or procedural clarification. Accurate approach documentation in operative notes prevents these queries.

Bilateral procedures present coding challenges when tumours involve multiple cardiac chambers. CCSD guidance permits coding K2310 twice when distinct tumours occupy separate chambers requiring separate excisions under different bypass arrests. However, continuous excision of a single tumour crossing chamber boundaries codes as one K2310 instance. The PHIN database tracks bilateral K2310 coding patterns, flagging providers whose bilateral rates exceed specialty norms for targeted audits.

Modifier usage remains minimal in CCSD coding compared to American CPT systems, but K2310 applies modifiers for unusual circumstances. Reoperative K2310 procedures for recurrent tumours append a “repeat procedure” indicator when performed beyond 90 days from initial surgery. Emergent K2310 cases for tumour rupture or embolisation append urgency modifiers affecting fee schedules. Clinic management platforms automate modifier assignment based on procedure timing and clinical documentation, reducing manual coding errors.

Compliance monitoring for K2310 involves internal audits of coded claims against operative notes, comparing documentation to billed procedures. Discrepancies indicating upcoding (billing K2310 for biopsy procedures) or unbundling (separately billing inherent components) require immediate correction. Self-reported coding errors to insurers before audit detection demonstrate good faith, often resulting in repayment without penalties. Waiting for insurer audits to identify errors escalates to fraud investigations, practice exclusion from provider panels, and regulatory referrals to the Care Quality Commission.

Expert Insights: Optimising K2310 Billing Workflows

Expert Picks

Struggling with pre-authorisation delays? Automated workflow software triggers pre-authorisation submissions the moment imaging confirms a cardiac tumour, reducing surgery scheduling delays from 14 days to 3 days.

Need to track bypass times across K2310 cases? Clinic dashboard management tools aggregate operative data, identifying surgeons whose average bypass times exceed specialty benchmarks and trigger insurer scrutiny.

Facing documentation gaps in K2310 claims? AI-powered clinical documentation extracts structured data from operative dictations, auto-populating tumour size, location, and bypass parameters into claim forms.

Conclusion

CCSD Code K2310: Excision of cardiac tumour represents one of cardiothoracic surgery’s most complex billing scenarios, demanding precise documentation, insurer-specific pre-authorisation, and meticulous coding accuracy. Benign tumour excisions follow relatively standardised pathways, while malignant tumours introduce variability in surgical extent, reconstruction requirements, and multidisciplinary coordination. Understanding fee schedule variations across Bupa, AXA PPP, Vitality, Aviva, and WPA enables realistic financial counselling for patients and accurate revenue forecasting for cardiac centres.

Success with K2310 billing hinges on comprehensive operative documentation capturing tumour characteristics, bypass parameters, and reconstruction techniques. Pre-authorisation compliance prevents claim denials, while appeals addressing specific denial reasons salvage rejected claims. Coding compliance through internal audits and modifier accuracy protects practices from regulatory scrutiny. For cardiac surgery teams managing private patients, K2310 coding proficiency directly impacts claim approval rates, payment timelines, and practice financial health.

Frequently Asked Questions